Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

de Novo Lesions in Native Coronary Arteries clinical trials

1 of 1 indexed de Novo Lesions in Native Coronary Arteries trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

de Novo Lesions in Native Coronary Arteries: 1 US clinical trial tracked, 1 recruiting.

de Novo Lesions in Native Coronary Arteries is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Boston Scientific Corporation, running 1 of these trials.

Enrollment posture brief

Registry condition de-novo-lesions-in-native-coronary-arteries

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

de Novo Lesions in Nativ (this)de Novo Lesions in Nativ (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near de Novo Lesions in Native Coronary Arteries

de Novo Lesions in Native Coronary Arteries lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for de Novo Lesions in Native Coronary Arteries on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. de Novo Lesions in Native Coronary Arteries is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Named interventions

Most-linked intervention names on de Novo Lesions in Native Coronary Arteries records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Plain old balloon angioplasty Procedure
1 trials
Drug eluting stent Device
1 trials
Drug Eluting Balloon Device
1 trials

US sites by state

Facility locations filed on de Novo Lesions in Native Coronary Arteries trials. A trial with sites in several states counts in each.

Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this de Novo Lesions in Native Coronary Arteries page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 de Novo Lesions in Native Coronary Arteries trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Boston Scientific Corporation sponsors the most de Novo Lesions in Native Coronary Arteries trials on record, review their full trial history before evaluating a specific study. See Boston Scientific Corporation's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This de Novo Lesions in Native Coronary Arteries condition card totals 1 registered trials; most-linked intervention Plain old balloon angioplasty; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.